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Abstract
Background: There is a need for evaluating community-based antiretroviral therapy (ART) delivery models to
improve overall performance of HIV programs, specifically in populations that may have difficulties to access
continuous care. This cluster-randomized clinical trial aims to evaluate the effectiveness of a multicomponent
differentiated ART delivery model (VIBRA model) after home-based same-day ART initiation in remote villages in
Lesotho, southern Africa.
Methods/design: The VIBRA trial (VIllage-Based Refill of ART) is a cluster-randomized parallel-group superiority
clinical trial conducted in two districts in Lesotho, southern Africa. Clusters (i.e., villages) are randomly assigned to
either the VIBRA model or standard care. The clusters are stratified by district, village size, and village access to the
nearest health facility. Eligible individuals (HIV-positive, aged 10 years or older, and not taking ART) identified during
community-based HIV testing campaigns are offered same-day home-based ART initiation. The intervention clusters
offer a differentiated ART delivery package with two features: (1) drug refills and follow-ups by trained and supervised
village health workers (VHWs) and (2) the option of receiving individually tailored adherence reminders and notifications
of viral load results via SMS. The control clusters will continue to receive standard care, i.e., collecting ART refills from a
clinic and no SMS notifications. The primary endpoint is viral suppression 12months after enrolment. Secondary
endpoints include linkage to and engagement in care. Furthermore, safety and cost-effectiveness analyses plus
qualitative research are planned. The minimum target sample size is 262 participants. The statistical analyses will follow
the CONSORT guidelines. The VIBRA trial is linked to another trial, the HOSENG (HOme-based SElf-testiNG) trial, both of
which are within the GET ON (GETing tOwards Ninety) research project.
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Discussion: The VIBRA trial is among the first to evaluate the delivery of ART by VHWs immediately after ART initiation. It
assesses the entire HIV care cascade from testing to viral suppression. As most countries in sub-Saharan Africa have
cadres like the VHW program in Lesotho, this model—if shown to be effective—has the potential to be scaled up. The
system impact evaluation will provide valuable cost estimations, and the qualitative research will suggest how the model
could be further modified to optimize its impact.
Trial registration: Clinicaltrials.gov, NCT03630549. Registered on 15 August 2018.
Keywords: HIV, cluster randomized controlled trial, village health worker, community health worker, home-based,
differentiated care and delivery, antiretroviral therapy, Lesotho, Southern Africa, multi component intervention
Introduction
Multiple studies conducted in sub-Saharan Africa (SSA)
report high attrition from HIV testing to linkage to care
and suboptimal engagement in care [1–7]. There are
many reasons for this, but structural barriers such as the
time-consuming and expensive (pre-)antiretroviral ther-
apy (ART) visits and subsequent regular drug refill visits
represent major impediments, especially in rural settings
[8–16]. Therefore, the World Health Organization
(WHO), international funders, national policies in sub-
Saharan Africa, and the research community are calling
for differentiated ART delivery models that are adapted
to the local context. These include further shifting of
tasks and the decentralization of care [17–23].
The CASCADE trial was a randomized clinical trial on
the effect of offering same-day ART vs the usual referral to
a health facility during home-based HIV testing on linkage
to care and viral suppression among adults with HIV in
Lesotho. This trial evaluated same-day ART initiation in
the community and found significantly improved outcomes
along the entire HIV care cascade [24]. However, the CAS-
CADE trial did not quite reach the targeted 90% linkage
to and engagement in care rates after participants had
tested positive for HIV and were offered same-day ART
initiation at home. The VIBRA (Village-Based Refill of
ART) trial builds on these findings, specifically addressing
the challenges after same-day home-based ART initiation.
For patients who are stable on ART, decentralization
of care to the community level and the shifting of care
tasks to lay health workers has been shown to be feas-
ible, cost-effective, and acceptable [25–40]. The WHO,
thus, endorses the recruitment of community health
workers as a strategy to mitigate the impact of the severe
shortage of nurses and doctors in rural Africa on health-
care coverage [41]. Moreover, the United Nations Pro-
gram on HIV/AIDS (UNAIDS) launched a plan to
recruit 2 million community health workers in Africa to
support its strategy [42]. Lesotho, a small landlocked
country surrounded by South Africa, has the second-
highest adult HIV prevalence globally (25.6%). More
than 70% of its population live in rural areas where there
is a shortage of doctors and nurses [43, 44]. A long-
standing public sector cadre of lay personnel, called
village health workers (VHWs), was introduced in 1978
and more than 4000 VHWs are currently successfully
operating in all districts of Lesotho [45].
We designed the VIBRA model in close collaboration
with local stakeholders. It is a multicomponent differen-
tiated ART delivery package that builds on the VHW
program and SMS technology. In this manuscript, we
describe the protocol for a cluster-randomized clinical
trial that aims to evaluate the effectiveness of the VIBRA
model following same-day home-based ART initiation in
rural communities in Lesotho.
Methods/design
Setting
The VIBRA trial will be conducted in the districts of
Butha-Buthe and Mokhotlong in northern Lesotho, in the
catchment areas of 22 health facilities. Both districts are
mostly rural with an estimated population of 220,000,
mainly living in villages scattered over a mountainous area
of 5842 km2. The trial utilizes the long-standing VHW
country program. VHWs are members of and appointed
by the community to provide a package of basic services
at the household level, although they have no formal pro-
fessional health education. They are elected by the village
members, complete 2 weeks of training followed by peri-
odic refresher courses, and are supported and supervised
by the health center staff for the corresponding catchment
area. Most are supported by the Ministry of Health and
receive a monthly stipend of USD 20.
Design
The VIBRA trial is a cluster-randomized superiority trial.
The trial is linked to another trial, the HOSENG
(HOme-based SElf-testiNG) trial [76]. Together, HOS-
ENG and VIBRA constitute the GET ON (GETing tO-
wards Ninety) research project. Reasons for this
interlinked design are that both trials rely on interven-
tions involving VHWs, who need to be randomized and
specifically trained, and that the HOSENG trial provides
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one of the recruitment platforms for VIBRA. Thus, the
two trials are based on the same cluster randomization
and will run in parallel. This design allows us to assess
the entire HIV care cascade in one larger project. A
cluster-randomized design was chosen because of the reli-
ance on VHWs and the high risk of cross-contamination
between study arms if randomization were done at the in-
dividual level.
Cluster randomization, screening of study participants,
eligibility and interventions
Cluster eligibility, cluster sampling, cluster randomization,
and the HIV testing campaign are described in detail in the
interlinked HOSENG study protocol, which has been
published separately [76]. In short, before the trial started,
the eligible clusters (i.e., villages) were randomized into four
groups: (1) VIBRA control and HOSENG control, (2)
VIBRA control and HOSENG intervention, (3) VIBRA
intervention and HOSENG control, and (4) VIBRA inter-
vention and HOSENG intervention. The randomization is
stratified by district, village size (≥30 vs < 30 households)
and access to the nearest health facility (easy vs hard to
reach, defined by needing to cross a mountain or river, or >
10 km away from the health facility), in a 1:1:1:1 allocation
ratio with block sizes of 4. In total, 159 clusters were identi-
fied and randomized into one of the four groups. When
enrolment started, 25 clusters per group, i.e., 50 clusters
per arm (VIBRA intervention vs control) were available to
the local study team with the option to add more clusters
as needed to reach the recruitment goals.
Campaign teams consisting of counsellors and one
study nurse visit the rural villages (clusters) in the two
study districts. The teams offer HIV testing and counsel-
ling and multi-disease screening and prevention. House-
hold members who are eligible for and consent, undergo
HIV testing by the counselors according to national HIV
testing guidelines [46]. All household members with a
confirmed HIV-positive result and not taking ART are
screened by the study nurse for VIBRA eligibility accord-
ing to the criteria in Table 1.
If a patient is eligible for VIBRA and consents, the
study nurse offers same-day home-based ART initiation
and proposes follow-up care according to the cluster as-
signment. As successfully implemented through our pre-
vious trial and recommended by the national guidelines,
same-day home-based ART initiation, using the national
standard first-line ART regimen, will be provided in
both arms [19, 24]. If individuals are not eligible for the
VIBRA trial and thus, not eligible for same-day standard
first-line ART initiation, they are referred to the health
facility. Features of same-day ART initiation are outlined
in Table 2.
Intervention clusters
The participants in the intervention clusters are offered
the two features of the VIBRA model. The first feature is
the possibility of village-based ART visits and refills
through the VHWs, with routine clinic visits required
only at 6 and 12 months after ART initiation. The sec-
ond is the offer of receiving a tailored SMS intervention.
Figure 1 summarizes the VIBRA model.
If participants in the intervention clusters choose the
village-based ART visits and refills, they are given an
appointment for a first clinical visit to the VHW 12 to
16 days after the home-based ART initiation. At each
visit, the VHW follows the same paper-based checklist
(provided as Additional file 1: eForm title “Follow-up”)
written in the local language (Sesotho). By following the
checklist, the VHW documents: (a) the patient’s symp-
toms to alert them to potential drug toxicity, opportun-
istic infections, or immune reconstitution inflammatory
syndrome, (b) adherence to ART, and (c) any visits to
other health facilities. To ensure safe and high-quality
clinical management, participants in intervention clus-
ters will not only be linked to their VHW, but will also
be under the care of the community ART nurse (CAN)
for the relevant district. If any question on the checklist
triggers an alert, the VHW will inform their CAN. CANs
are nurses who are experienced in HIV care. One CAN
per district has been hired. The VHWs and CANs will
have a list of the participants for whom they are
Table 1 Eligibility criteria for VIBRA trial
Inclusion criteria Exclusion criteria
Individual is a member of a visited household, i.e. the individual
is (a) acknowledged by the household head or their representative
as part of the household and (b) sleeps in the household regularly
(at least once a month)
HIV-positive individual is on ART or stopped less than 30 days ago
Individual is confirmed HIV-positive, as determined by two reactive
blood-based HIV antibody tests according to national guidelines
HIV-positive individual is physically, mentally, or emotionally not able to
participate in the study, in the opinion of the study nurse
Individual has never taken ART (ART naïve) or has stopped ART more
than 30 days prior (ART defaulter according to national guidelines)
HIV-positive individual is in care for hypertension or diabetes; documentation
or proof of medication is needed
Individual is ≥10 years old and body weight≥ 35 kg HIV-positive individual wishes to get care outside the two study districts
ART antiretroviral therapy, HIV human immunodeficiency virus
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responsible. A VHW will be allowed to dispense ART
only to participants on their list. Like the health facilites,
the VHW will provide a supply of drugs for 1–3 months
at each visit. Participants are, however, encouraged to
visit the VHW or the clinic at any time when problems
or questions arise. Six months after ART initiation, the
participant must attend the clinic for the first time for a
laboratory assessment.
VHWs have monthly meetings at the health facility with
a designated facility staff member. The VIBRA model will
utilize these existing meetings and the CAN (or a repre-
sentative) will join and provide support. These meetings
are a platform for reviewing patient files. Patients can be
up-referred (to the health facility) or down-referred (to
the VHW). If a patient misses an ART visit, they will be
traced by the VHW using a standardized tracking tool
(provided as Additional file 1: eForm title “Tracing form”).
All VHWs in the intervention clusters will be trained to
deliver the VIBRA model: (a) to dispense ART (and other
co-medications such as cotrimoxazole), (b) to screen for
ART-related adverse events and drug toxicities, (c) to
screen for co-infection (especially tuberculosis), (d) to as-
sess adherence, (e) to understand the referral algorithm in
case there is clinical deterioration, (f) to address disclosure
and keep confidentiality, and (g) to perform basic data
entry for the checklists. This training will last for 2–3 days.
If participants in the intervention clusters choose the
SMS intervention, they will receive monthly reminder
SMS in Sesotho to adhere to ART (“Take your medication
regularly as prescribed and don’t run out of medication”)
and a viral load (VL) result-triggered SMS after the 6- and
12-month follow-up visits:
– If undetectable VL (< 20 copies/mL):
“Congratulations, your lab test was good. Keep it up!”
– If detectable VL (≥20 copies/mL): “Your lab test
results are back. Make sure to come to the health
facility as soon as possible and remind the nurse
about your lab test.”
– If technical failure of VL measurement: “The lab test
was unsuccessful. Make sure to come to the health
facility as soon as possible and remind the nurse
about your lab test.”
To maintain participant confidentiality, messages will not
explicitly mention HIV or HIV care. Participants are not
asked to confirm receipt of messages or to reply and can
choose at any time to opt out from receiving messages.
Control clusters
Participants in the control clusters are offered standard
care, i.e., ART visits and refills at the health facility and
no SMS intervention. They receive an appointment for a
first clinic visit within 12 to 16 days of the home-based
ART initiation. For each visit, a staff member at the
Fig. 1 Procedures for the VIBRA intervention and control clusters
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health facility will fill in the same checklist as the
VHWs. Study participants will not be offered any other
differentiated delivery models.
Endpoints
The primary endpoint is viral suppression (< 20 copies/mL)
at 12months, defined as the proportion of all participants
with a suppressed VL 12months (range: 10–15months)
after enrollment. Although this is a cluster-randomized
trial, the analysis will be at individual level with viral
suppression as a binary outcome. VL will be measured in
plasma using the COBAS TaqMan® HIV-1 Test, v2.0
(Roche Diagnostics). Secondary and exploratory endpoints
as well as the long-term follow-up are outlined in Table 3.
Additional research within the project
We will conduct biomolecular research within this pro-
ject. We will assess the prevalence of major drug resist-
ance mutations in baseline samples and on all samples
with unsuppressed VL at 12 months. Participants who
start ART at home during the testing campaign but sub-
sequently never link to care will be specifically traced to
assess the development of drug resistance mutations.
Qualitative research is planned alongside the project
to provide important contextual data and an in-depth
exploration of the community response to the interven-
tion. For a qualitative case–control study, a random sam-
ple from the VIBRA intervention clusters will be chosen.
Cases will be participants who refuse village-based ART
refills through the VHW, while controls will be partici-
pants who accept village-based ART refills through the
VHW. Moreover, we will conduct standardized interviews
with a random sample of all stakeholders involved in
delivering this new ART care and delivery model.
We will perform a system impact evaluation and cost-
effectiveness analysis to estimate the impact of the VIBRA
intervention on health benefits and costs. First, we will as-
sess the direct costs of the interventions. Secondly, we will
assess the cost-effectiveness of the VIBRA model. Thirdly,
we will assess the economic burden of the interventions to
the participants, i.e., including both direct costs and the
opportunity costs of their time. The assessment of direct
costs will include staff costs (campaign staff, clinical staff,
laboratory staff, VHWs, and CANs), personnel training
costs, the cost of equipment (costs of HIV tests, costs of
ART and other drugs, and laboratory costs including the
point-of-care tests at enrolment), and non-medical costs
for the participant. The VIBRA model is expected to re-
duce the number of clinic visits because of the VHW-
based ART refill. There are expected to be fewer unsched-
uled visits because the intervention may lead to a better
and more sustained clinical outcome. This would decrease
costs for the health system and the participants (i.e., time
required to access care, lost working time while accessing
care, and additional expenses while accessing care).
Data collection and management, biologic material, and
follow-ups
The VHWs and the healthcare staff at the health facil-
ities will collect data from scheduled and unscheduled
ART visits on standardized paper study forms (case
report forms), which are the source documents. Case
report forms will be collected regularly by the study
team and entered into a password-protected database
(MACRO, Elsevier). Similarly, data relevant for the SMS
intervention will be entered and stored in a separate
encrypted and password-protected online database. This
offers the possibility of sending out SMS messages auto-
matically and is connected to the district laboratory
database containing the VL results. The platform and
data are housed on a dedicated server in a data center in
Switzerland (Interxion, managed by Hostpoint AG),
which meets FINMA-RS 08/07 requirements, is ISO-
27001-certified, and encrypts data in-transit with SSL
and all patient names at-rest using OpenSSL with the
AES-256-CTR cipher method. Access to both platforms
is strictly limited and regulated through personal user
profiles. SMS messages are dispatched using the trusted
third-party provider Twilio, headquartered in the United
States and certified with the EU–U.S. and Swiss–U.S.
Privacy Shield Framework. Consent forms will be stored
securely in the headquarters of the study center (the
SolidarMed office in Butha-Buthe, Lesotho). Participant
files will be maintained in storage for at least 10 years
after completion of the study.
Participants in all clusters undergo HIV testing and
phlebotomy at enrolment, and phlebotomy at 6 and 12
months. For each participant, blood samples coded with
the participant’s study ID will be stored at − 80 °C at the
laboratory in Butha-Buthe Hospital. All samples collected
fall under the biobank and material transfer agreement,
which has been approved by the ethics committees in
Switzerland and Lesotho. Figure 2 is the SPIRIT flow dia-
gram and has an overview of data collection, laboratory
assessments, and follow-up visits (Additional file 2).
Sample size
Based on data from the CASCADE trial [24], we expect
the proportion of patients engaged in care with docu-
mented viral suppression 12months after same-day ART
initiation in the control arm to be approximately 50%
and we expect to recruit on average 4 individuals per
cluster. Assuming a 20% refusal and ineligibility rate,
about 400 individuals need to be screened to identify
320 eligible individuals and 90% power to detect a 20%
increase in the intervention group. We plan to enroll a
minimum of 262 patients to ensure a minimum power
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Table 3 Secondary and exploratory endpoints of the VIBRA trial
Definition Time point following
enrolment
Remarks
Secondary endpoints
Viral suppression < 20 copies/
mL
Proportion of all participants with viral
suppression (< 20 copies/mL)
6 (range: 5–8) months
Viral suppression < 1000 copies/
mL
Proportion of all participants with viral
suppression (< 1000 copies/mL)
6 (range: 5–8) and 12 (range:
10–15) months
Some of the remote health facilities in
our study districts face regular
challenges in sending blood samples to
a government hospital. To ensure there
are sufficient VL measurements among
our study participants, these health
facilities will be equipped with dried-
blood-spot kits as a backup for VL mea-
surements. According to WHO, the rec-
ommended threshold for treatment
failure using a dried blood spot is 1000
copies/mL
Linkage to care Proportion of all participants attending
their first clinic- or VHW-based ART visit
at least once within the given period
a) Within 1 month
b) Within 3 months
Engagement in and retention in
care
Proportion of all participants active in
care at a health facility or with a VHW
6 (range: 5–8) and 12 (range:
10–15) months
Active in care is defined as at least one
ART visit in the defined window.
Patients who have stopped ART and
those who have transferred to another
health facility with a known outcome
(documented proof of a follow-up visit
or laboratory test) are included. Partici-
pants who have died, are lost to follow-
up, who have transferred to another fa-
cility without a known outcome (no
documented proof of a follow-up visit
or laboratory test), or are more than 2
months late for a scheduled consult-
ation or medication pick-up with a rea-
son (e.g. currently no money for a clinic
visit, busy working in South Africa, etc.)
are not counted as being active in care
All-cause mortality Proportion of participants dead for any
reason
12 (range: 10–15) months Verbal autopsy to determine cause of
death whenever possible; death
certificates and autopsy reports are not
required
Lost to follow-up Proportion of all participants lost to
follow-up
12 (range: 10–15) months We define participants lost to follow-up
if they or their treatment buddies are
more than 2months late for a sched-
uled consultation or medication pick-up
and we have no recent information
about the participant
Transfer out Proportion of all participants who
transferred to another health facility
(other than the one they were initially
attached to) with a known outcome
12 (range: 10–15) months As above, a known outcome is
documented proof of a follow-up visit
or laboratory test at the new health
facility
Serious adverse event Proportion of patients with a serious
adverse event
Within 12 months Serious adverse events graded
according to the Division of AIDS Table
for Grading the Severity of Adult and
Pediatric Adverse Events, Version 2.0,
November 2014
Exploratory endpoints
Compliance with the protocol
procedure
Proportion of ART refills and ART visits
per participant according to the
protocol schedule, at the VHW and the
health facility
12 (range: 10–15) months
Overall effect of HOSENG +
VIBRA
Overall effect of the combined
interventions HOSENG and VIBRA (arm 4
12 (range: 10–15) months
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of 80%. Based on the assumption that we will recruit
about 4 individuals per cluster, we will begin with 50
clusters per arm and can add more clusters as needed to
reach our recruitment goals. All sample size calculations
were done assuming a type 1 error rate of 0.05 and an
intra-cluster correlation coefficient of 0.015. If the true
number of eligible individuals per cluster is lower and
thus more clusters will be needed to reach the targeted
minimum sample size, this will result in an increase of
power. Table 4 provides estimates of the sample size
under varying recruitment scenarios.
Analyses
Analyses will be performed following the CONSORT
guidelines for cluster-randomized trials [47] and an
intention-to-treat principle including all participants as
randomized per cluster randomization. Clusters are the
unit of randomization, but individuals are the unit of ana-
lysis. As we expect to have many clusters (i.e., villages) with
few eligible individuals (i.e., HIV-positive but not on ART),
an individual-level analysis is most appropriate. Multi-level
statistical models will be used to adjust for the clustered
data. The following analysis sets will be used in this trial:
Table 3 Secondary and exploratory endpoints of the VIBRA trial (Continued)
Definition Time point following
enrolment
Remarks
vs arm 1) on viral suppression (< 20
copies/mL)
Assessment of acceptance of
interventions
a) Acceptance of same-day ART
initiation
b) Acceptance of VIBRA model
Within 1 month
Long-term follow-up
Long-term follow-up Proportion of participants who are
active in care and virologically
suppressed (< 20 copies/mL)
24 (range: 22–28) months
The denominator of all proportions is the total number of study participants enrolled. Although this is a cluster-randomized trial, these endpoints will be analyzed
at the individual level with binary outcomes
ART antiretroviral therapy, VHW village health worker, VL viral load
Fig. 2 SPIRIT flow diagram for the VIBRA trial.
Footnotes: 1see Additional file 1, 2only at clinic-based follow-up visits, 3for all participants with a baseline CD4-count <200 cells/mcL (see also Table 2),
4incl. CTX and IPT (+B6) and other co-infection (prophylaxis) medication if appropriate, 5See chapter Additional research within the project
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1. Intention-to-treat set: All study participants will be
evaluated according to their cluster assignment at
randomization.
2. Cluster per-protocol set: This set includes all partic-
ipants from clusters that completed the study with-
out a major protocol deviation.
3. Individual per-protocol set: This set includes all
participants who completed the study without a
major protocol deviation.
The primary analysis for the VIBRA study will be the
comparison of viral suppression at 12months after the
offer of same-day ART initiation in the intention-to-treat
set. The primary analysis will use a multi-level logistic re-
gression model to assess the difference between the arms,
adjusted for the prespecified randomization stratification
factors and the clustering according to village. Moreover,
we will adjust for the most important baseline characteris-
tics if found to be unbalanced (gender, age, known HIV
status vs newly diagnosed, ever on ART vs never on ART,
CD4 count) and other factors found to be largely unbal-
anced between the intervention and control clusters.
Baseline characteristics will be presented according to
randomized groups and no formal testing will be per-
formed. Categorical variables will be described as absolute
and relative frequencies and continuous variables as me-
dians and interquartile ranges. As with the primary
analysis, secondary endpoints will be analyzed with a multi-
level logistic regression model. All results will be presented
as odds ratios and their respective 95% confidence intervals.
Several sensitivity analyses will be conducted. We will do a
quadrature check of the model fit and if found to be unreli-
able, we will utilize generalized estimating equations. The
effect of sociodemographic and clinical determinants (age
groups, gender, education status, employment status,
WHO stage, CD4 count, tuberculosis status, CAGE status,
HIV/ART history, and HIV knowledge) on key study
outcomes will be assessed by including interaction terms in
the model. If an interaction term is found to be significant,
effect estimates will be summarized descriptively by sub-
group. As the study is not powered for these pre-planned
subgroup analyses, these results will be considered explora-
tory. Where data are missing in important covariates, mul-
tiple imputation will be utilized and the results compared
to models ignoring missing data.
All analyses will be done using Stata (version 14, Stata
Corporation, Austin, Texas, USA), using two-sided p
values and a significance level of 0.05.
Monitoring, auditing, and data safety and monitoring
board
At least one external monitoring visit will assess adher-
ence to the approved trial protocol, and the accuracy of
completed case report forms and the electronic dataset.
The VIBRA trial is researching the implementation of a
treatment. The safety profiles of all drugs used are well
known, and the intervention does not include any new
drugs. Moreover, there have been encouraging results
from similar trials in Uganda, Kenya, and Tanzania [48–
50]. Thus, major adverse effects on patients’ health from
this intervention are not expected. Participants in the
VIBRA model can opt to switch back to usual care or be
referred to facility-based care at any time during the trial
period. Therefore, we do not intend to establish a data
safety and monitoring board. However, a separate,
detailed safety monitoring plan has been developed to
handle adverse events and serious adverse events in
line with Swiss and Basotho ethics regulations. Ad-
verse events and serious adverse events will be graded
according to the Division of AIDS Table for Grading
the Severity of Adult and Pediatric Adverse Events,
Table 4 Sample size estimations for the VIBRA trial
Control rate of
viral suppression
Intervention rate of
viral suppression
Power Intra-cluster correlation
coefficient
Average number of eligible
individuals per cluster
Total number
of clusters
Total
sample size
0.5 0.7 0.9 0.015 4 120 478
0.5 0.7 0.9 0.015 3 160 478
0.5 0.7 0.9 0.015 2 240 478
0.5 0.7 0.8 0.015 4 66 262
0.5 0.7 0.8 0.015 3 88 262
0.5 0.7 0.8 0.015 2 130 262
0.5 0.75 0.9 0.015 4 49 195
0.5 0.75 0.9 0.015 3 65 195
0.5 0.75 0.9 0.015 2 98 195
0.5 0.75 0.8 0.015 4 33 130
0.5 0.75 0.8 0.015 3 44 130
0.5 0.75 0.8 0.015 2 65 130
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Version 2.0., November 2014 [51] and managed ac-
cording to the standard procedure for each study site
following the national guidelines [19]. The study phy-
sicians are responsible for all safety procedures. If a
participant reports an adverse event of grade 2 or
higher at their last study visit, they will remain under
observation by the study physicians, even after study
termination, until the adverse event is resolved or
stabilized.
Discussion
Effective and differentiated strategies are needed to im-
prove the HIV care cascade, especially in rural settings.
Despite successful upscaling of ART, the financial, human,
and physical resources available to fulfill the UNAIDS tar-
gets are unlikely to grow relative to the increasing number
of people on ART [52, 53]. Therefore, there is global con-
sensus that new differentiated care and service delivery
models that increase the capacity, efficiency, and cost-
effectiveness of delivering ART without reducing quality
of care are urgently needed [22, 39, 54].
Shifting tasks to lay health workers in the community is
a promising approach and in line with the current
UNAIDS initiative [42]. However, at community level,
task-shifting usually focuses on adherence monitoring, not
the provision of antiretroviral drugs [29, 55–61]. A few
programs use community health workers or VHWs to
supply ART at home to patients [48, 49, 62–67]. This is,
however, a resource-intensive intervention, there may be
difficulties with confidentiality and stigma relating to
home visits, patients must be at home during these visits,
and their homes need to be readily accessible. These fac-
tors are unfavorable in a setting like Lesotho with limited
resources and a population scattered around a vast moun-
tainous area. Moreover, these models include only stable
patients. The definition of a stable patient can be challen-
ging, and may lead to late inclusion in these models. Dif-
ferentiated care should be designed not only for stable
patients but also for patients who would otherwise not en-
gage in care [23].
The VIBRA model entails a second feature, SMS re-
minders and notifications. These have been studied
widely in sub-Saharan Africa and lead to increased ad-
herence and engagement in care [68–74]. However, sus-
tainability is questionable, especially when reminders
must be implemented manually. Our setting in Lesotho
allows SMS messages to be sent automatically from an
established database that is connected to the govern-
mental district laboratory database with access to VL re-
sults from all study districts. Moreover, while most
studies use standardized messages reminding the patient
about their drug intake or clinic visits, the SMS inter-
vention in the VIBRA model will go one step further. It
will automatically generate and send notifications that
are individually tailored according to the VL level, indi-
cating the next steps of action for the patient.
This trial has several limitations. First, the study design
does not allow for the evaluation of the effectiveness of
each individual feature of the VIBRA model. Second, as
in most operational research studies, we will have little
control over what happens in our standard care arm.
Standard care for HIV continues to evolve rapidly with
frequent guideline revisions and the implementation of
other differentiated ART service delivery models. Third,
due to the nature of this pragmatic implementation trial,
it is not possible to fully blind participants or staff to the
intervention. However, allocation will be concealed from
the study participants due to the cluster randomization
design, which implies randomization before participant
inclusion.
In summary, the VIBRA trial evaluates a unique differ-
entiated ART delivery model with community-based drug
refills and follow-ups after a home-based diagnosis and
ART initiation in combination with a tailored SMS ser-
vice. As most countries in sub-Saharan Africa have cadres
like the VHW program in Lesotho, this model—if shown
to be effective—has the potential to be scaled up. The sys-
tem impact evaluation will provide valuable cost estima-
tions, and the qualitative research will suggest how the
model could be modified further to optimize its impact.
Trial status and recruitment
The trial was launched on 16 August 2018 in both study
districts. Based on the experience of previous HIV test-
ing campaigns and the CASCADE trial, we assumed that
we would reach the required minimum target sample
size in about 6–8 months. The initial study protocol, ver-
sion 5, was submitted to the ethics committees in
Lesotho (February 2018) and Switzerland (April 2018),
and approved on 25 April 2018 (Lesotho) and 8 May
2018 (Switzerland). Meanwhile, two minor amendments
to the study protocol were submitted and have been ac-
cepted. The current protocol is version 7 and was ap-
proved in October 2018.
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